Academic Pharmaceuticals Inc, the partner of Pharmaceutics International Inc, has received US Food and Drug Administration (FDA) approval for Bretylium Tosylate Injection USP, 500mg/10mL (50 mg/mL) Single-Dose Vials, it was reported yesterday.
The product is indicated for the prophylaxis and therapy of ventricular fibrillation; treatment of life-threatening ventricular arrhythmia that has failed to respond to first-line antiarrhythmic agents. Pharmaceutics International Inc is the exclusive manufacturer of Bretylium Tosylate for Academic Pharmaceuticals Inc, which is presently seeking a commercial partner to license and launch the drug product in the US.
Dr John Somberg, president of Academic Pharmaceuticals Inc, said, 'We are pleased to gain approval of this additional therapy to treat ventricular fibrillation offering health care providers alternative options to treat this life-threatening condition. Bretylium Tosylate Injection USP, 500mg/10 mL is the 11th FDA product approval and 3rd injectable product approval, for Pii and its partners, during the past two years. This most recent approval follows the tentative approval of the first syringe product filed from Pii, thus expanding Pii's injectable product offering to include terminally sterilised vials, aseptically filled vials, and syringe products.'
Dr Syed Abidi, Pii's chairman and CEO, added, 'Bretylium Tosylate is a uniquely effective agent for the treatment of ventricular tachycardia and ventricular fibrillation in a cardiac arrest. It is the only drug that can pharmacologically convert ventricular fibrillation, it is an alternative to Amiodarone and more effective than Lidocaine.'
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML